Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Biktarvy versus Symtuza in newly diagnosed HIV infection in a test-and-treat setting
2019-003208-11Phase 3Unknown
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in human immunodeficiency virus infection (HIV) comparing Biktarvy arm with Symtuza arm (2 arms). Primary endpoint: Primary virological response. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-003208-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003208-11.